{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-304012","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.531041+00:00","generated_at":"2026-06-07T06:58:56.063183+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Royalty Pharma ups revolving credit facility to $1.8B, extends majority to Dec 2028","bullets":["Borrowing capacity increased from $1.5B to $1.8B via Amendment No. 3.","$1.69B of commitments extended to December 22, 2028; $110M remains at Oct 31, 2027.","Facility remains unsecured; interest based on SOFR/base rate plus applicable margin.","Covenants include max leverage ratio of 4.00x (4.50x post material acquisition) and min coverage of 2.50x.","Proceeds for general corporate purposes; amendment effective December 22, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-304012","json":"https://secwatch.observer/filing/0001193125-23-304012.json","markdown":"https://secwatch.observer/filing/0001193125-23-304012.md","text":"https://secwatch.observer/filing/0001193125-23-304012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523304012/0001193125-23-304012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523304012/d656258d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:58:56.063183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd6110a42f3845a676a8dbadc10a3a3600f78dda","claim":"Royalty Pharma plc amended \"Third Amendment\" with Bank of America, N.A., as Administrative Agent and the other lenders thereto valued at increases the borrowing capacity under the Credit Agreement from $1.5 billion to $1.8 billion (effective 2023-12-22).","evidence_excerpt":"On December 22, 2023, Royalty Pharma plc (the “Company”) and Royalty Pharma Holdings Ltd., a non-wholly owned consolidated subsidiary of the Company, entered into Amendment No. 3 (the “Third Amendment”) to the Amended and Restated Revolving Credit Agreement, dated as of September 15, 2021, as amended by Amendment No. 1 to Credit Agreement, dated as of October 31, 2022 and as further amended by Amendment No. 2 to Credit Agreement, dated as of May 16, 2023, with Bank of America, N.A., as Administrative Agent and the other lenders thereto (as so amended, the “Credit Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523304012/0001193125-23-304012-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Bank of America, N.A., as Administrative Agent and the other lenders thereto"},{"label":"Value","value":"increases the borrowing capacity under the Credit Agreement from $1.5 billion to $1.8 billion"},{"label":"Effective","value":"2023-12-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}